BALAXI2023-07-012023-09-30 BALAXI2023-07-012023-09-30 BALAXI2023-07-012023-09-30in-bse-fin:OneOperatingExpenses01Member BALAXI2023-07-012023-09-30in-bse-fin:FourOperatingExpenses01Member BALAXI2023-09-30 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares BALAXI NOTLISTED BALAXI PHARMACEUTICALS LIMITED Equity 2023-04-01 2024-03-31 2023-11-02 2023-10-26 INR Lakhs Half yearly 11:30:00 14:45:00 2023-11-02 2023-11-02 true Cash Flow Indirect Not applicable Single segment Specialized Wholesale 2023-07-01 2023-09-30 Unaudited Consolidated 547209000.00 2799000.00 550008000.00 291206000.00 0.00 0.00 65624000.00 3681000.00 6610000.00 82735000.00 449856000.00 100152000.00 56456000.00 156608000.00 12351000.00 -29000.00 12322000.00 0.00 144286000.00 0.00 0.00 0.00 0.00 144286000.00 -56678000.00 87608000.00 144286000.00 0.00 87608000.00 0.00 102302000.00 10 14.10 14.06 0.00 0.00 14.10 14.06 1. The Unaudited Consolidated Financial Results for the Quarter and Half year ended September 30, 2023 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on November 02, 2023. The Consolidated Financial Results are prepared in accordance with the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013. 2. Previous period figures have been regrouped, re-arranged and re-classified wherever necessary to conform to current period’s classification. 3. The operating segment of the Group is identified as Specialized Wholesale as the Chief Operating Decision Maker reviews business performance at an overall level as one segment. Therefore, the disclosure as per Regulation 33 (1)(e ) read with Clause L of Schedule IV of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is not applicable to the Company. 4. During the current quarter, unrealised loss recognised in previous quarter profit and loss account has been reversed to the extent of INR 5.65 Cr. As mentioned previously, inventory lying in the books continues to be sold at substantially higher than the carrying value and profits will continue to be recognised as and when realised. Single segment 2023-04-01 2023-09-30 Unaudited Consolidated 1206763000.00 -7282000.00 1199481000.00 694340000.00 0.00 0.00 134498000.00 6576000.00 9463000.00 181879000.00 1026756000.00 172725000.00 -410238000.00 -237513000.00 31691000.00 -60000.00 31631000.00 0.00 -269144000.00 0.00 0.00 0.00 0.00 -269144000.00 -5429000.00 -274573000.00 -269144000.00 0.00 -274573000.00 0.00 102302000.00 10 -26.33 -26.10 0.00 0.00 -26.33 -26.10 Administrative Expenses 82735000.00 Administrative Expenses 181879000.00 177541000.00 0.00 0.00 254906000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 78278000.00 510725000.00 852215000.00 0.00 444564000.00 281430000.00 0.00 25413000.00 0.00 751407000.00 0.00 30371000.00 1633993000.00 0.00 0.00 2144718000.00 102302000.00 1452413000.00 1554715000.00 1554715000.00 4016000.00 0.00 0.00 4016000.00 17145000.00 10945000.00 0.00 0.00 32106000.00 183323000.00 296643000.00 0.00 479966000.00 3458000.00 74473000.00 0.00 0.00 557897000.00 0.00 0.00 590003000.00 2144718000.00 6575000.00 198018000.00 89691000.00 0.00 -37409000.00 0.00 0.00 -8937000.00 0.00 -68160000.00 0.00 0.00 0.00 9463000.00 0.00 0.00 0.00 -4995000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 184246000.00 -53267000.00 0.00 0.00 0.00 7854000.00 -5429000.00 -66549000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 28316000.00 41219000.00 0.00 0.00 0.00 0.00 0.00 2671000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -15574000.00 0.00 0.00 16557000.00 0.00 0.00 0.00 0.00 0.00 71131000.00 0.00 468000.00 0.00 0.00 5819000.00 0.00 0.00 81401000.00 -723000.00 0.00 -723000.00 282152000.00 281430000.00 -56678000.00 -5429000.00 0.00 0.00 0.00 0.00